Clinical Trial Detail

NCT ID NCT03773302
Title Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors QED Therapeutics, Inc.
Indications

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine

BGJ398

Age Groups: adult senior

Additional content available in CKB BOOST